Key highlights
- DARZALEX net trade sales in Q1 2026 were USD 3,964 million.
- Sales split: U.S. USD 2,208 million; rest of world USD 1,756 million.
- Includes subcutaneous DARZALEX FASPRO (daratumumab + hyaluronidase-fihj) in the U.S., with Genmab receiving royalties under J&J's exclusive license.
Q1 2026 sales
Net trade sales of DARZALEX totaled USD 3,964 million in Q1 2026.
Geographic split
U.S. sales were USD 2,208 million and rest-of-world sales were USD 1,756 million.
Product and royalties
The figures include subcutaneous DARZALEX FASPRO (daratumumab plus hyaluronidase-fihj) in the U.S.; Genmab receives royalties on worldwide net sales of both the intravenous and subcutaneous daratumumab products under an exclusive license to Johnson & Johnson (Janssen Biotech, Inc.).
